SCHEMBL325206

SCHEMBL325206

O=C(OCc1cccc(Cl)c1)N1C=Cc2ccccc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.43
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP12 P39900 1/20 0.41
HSD17B3 P37058 1/20 0.41
ENPP2 Q13822 2/20 0.41
NR4A2 P43354 1/20 0.40
P2RX4 Q99571 1/20 0.40
HTT P42858 1/20 0.39
MAOB P27338 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
ATXN2 Q99700 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324120 0.87 P2RX4 (0.46) MMP1MMP2MMP9MMP12HSD17B3
SCHEMBL324299 0.86 P2RX4 (0.52) P2RX4MEN1KMT2AALDH1A1NPC1
SCHEMBL324589 0.86 GRIN2B (0.41) MMP2MMP9MMP12HSD17B3P2RX4
SCHEMBL323355 0.86 HCAR2 (0.43) HCAR2MMP1MMP2MMP9MMP12
SCHEMBL323321 0.84 NPC1 (0.47) MMP1MMP2MMP9MMP12P2RX4
SCHEMBL323429 0.83 PRKCA (0.46) MMP1MMP12ENPP2NR4A2MAOB
SCHEMBL324049 0.83 FFAR1 (0.40) P2RX4MAOBMAOA
SCHEMBL325232 0.83 HSD17B3 (0.46) HSD17B3PTGDR2
SCHEMBL324441 0.83 HSD17B3 (0.43) HSD17B3PTGDR2
SCHEMBL323930 0.83 HSD17B3 (0.46) HSD17B3ENPP2NR4A2HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 HCAR2 107/4885MMP1 3638/4885MMP2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.